Neurology and Therapy最新文献

筛选
英文 中文
Clinically Meaningful Reduction in Seizure Frequency in Patients with Tuberous Sclerosis Complex Treated with Cannabidiol. 大麻二酚治疗结节性硬化症患者癫痫发作频率的临床意义降低。
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-11-13 DOI: 10.1007/s40120-026-01075-y
Elizabeth A Thiele, Teresa Greco, Charlotte Nortvedt, Kishan Vyas, Rima Nabbout
{"title":"Clinically Meaningful Reduction in Seizure Frequency in Patients with Tuberous Sclerosis Complex Treated with Cannabidiol.","authors":"Elizabeth A Thiele, Teresa Greco, Charlotte Nortvedt, Kishan Vyas, Rima Nabbout","doi":"10.1007/s40120-026-01075-y","DOIUrl":"https://doi.org/10.1007/s40120-026-01075-y","url":null,"abstract":"<p><strong>Introduction: </strong>In antiseizure medication clinical trials, a ≥ 50% reduction in seizure frequency is a relatively standard primary efficacy endpoint, but the real-world threshold for response perceived as clinically impactful for patients with tuberous sclerosis complex (TSC) is largely unassessed. We investigated this threshold in patients with TSC from the randomized controlled trial evaluating cannabidiol (CBD; Epidyolex<sup>®</sup> [EU]/Epidiolex<sup>®</sup> [USA]; ClinicalTrials.gov ID: NCT02544763).</p><p><strong>Methods: </strong>This post hoc analysis used receiver operating characteristics (ROC) to quantify thresholds at which monthly seizure frequency reduction could be deemed clinically important in pooled data from patients receiving 25 or 50 mg/kg/day CBD (n = 132) for 16 weeks. Reductions in seizure frequency were anchored to Caregiver Global Impression of Change (CGIC; caregiver-reported assessment tool) ratings of 'slightly improved' or better, or 'much improved' or better. Anchor-based methods and distribution-based methods were applied to determine the thresholds for a clinically important response and minimal clinically important difference, respectively.</p><p><strong>Results: </strong>The best-fit ROC-derived threshold for a clinically important response associated with a CGIC of 'slightly improved' or better was a 33% reduction in seizure frequency; for 'much improved' or better, the threshold was a 52% reduction. Thresholds for the minimal clinically important difference, based on half standard deviation (standard error of the mean), were - 17.8% (- 19.5%) for a CGIC rating of 'slightly improved' or better, and - 17.2% (- 18.9%) for CGIC rating of 'much improved' or better. Spearman's correlation was 0.54 (P < 0.001).</p><p><strong>Conclusion: </strong>When anchored to a CGIC rating of 'slightly improved' or better, the threshold for a clinically important response in seizure reduction was 33%, suggesting that a cut-off of 50% may overlook patients who are achieving meaningful improvements in their overall condition, as perceived by their caregivers. This exploratory analysis may help physicians to ascertain the level of improvement that patients and caregivers perceive as beneficial in TSC, particularly when seizure reductions are < 50%.</p><p><strong>Clinical trial registration number: </strong>ClinicalTrials.gov ID: NCT02544763.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149408825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Trofinetide Treatment Persistence and Dosing Patterns in Rett Syndrome: A Post Hoc Analysis of Linked Trial and Real-World Specialty Pharmacy Data. 特罗非肽治疗Rett综合征的长期持续性和给药模式:关联试验和现实世界专业药房数据的事后分析。
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-11-13 DOI: 10.1007/s40120-026-01083-y
Nazia Rashid, Krithika Rajagopalan, Vinod Kumar Yakkala
{"title":"Long-Term Trofinetide Treatment Persistence and Dosing Patterns in Rett Syndrome: A Post Hoc Analysis of Linked Trial and Real-World Specialty Pharmacy Data.","authors":"Nazia Rashid, Krithika Rajagopalan, Vinod Kumar Yakkala","doi":"10.1007/s40120-026-01083-y","DOIUrl":"https://doi.org/10.1007/s40120-026-01083-y","url":null,"abstract":"<p><strong>Introduction: </strong>Trofinetide (TRO) approval by the US FDA enabled participants from the placebo-controlled (LAVENDER) and open-label extension (LILAC-1 and LILAC-2) trials to continue TRO commercially. We assessed participant characteristics, adverse events (AEs), dosing patterns, and time on TRO among LILAC-2 participants who continued or did not continue TRO post-approval.</p><p><strong>Methods: </strong>This retrospective post hoc analysis used participant-level data from the LAVENDER, LILAC-1, and LILAC-2 trials linked with specialty-pharmacy data to categorize TRO continuers and non-continuers by post-launch prescription (RX) shipment status. Demographics (e.g., age, race) were evaluated at baseline (LAVENDER). Outcomes included Rett Syndrome Behavior Questionnaire (RSBQ) total and domain scores, Clinical Global Impression-Improvement (CGI-I) score from baseline through LILAC-2, highest recorded AE severity for each AE during LILAC-2, and dosing patterns (mean twice-daily dose by volume [ml], weight [mg/kg]; percent target daily dose [%TDD]) pre- and post-launch. Post-launch treatment persistence (allowable RX shipment gap ≤ 90 days) and time on TRO were also assessed.</p><p><strong>Results: </strong>Among 77 LILAC-2 participants alive and eligible (n = 73) to shift to real-world usual care, 57/73 (78.1%) were classified as TRO continuers; the rest were non-continuers. Baseline mean age was 10.5 vs 11.9 years; most were white (89.5% vs 100.0%). Both groups achieved clinically meaningful total RSBQ improvement from baseline to LILAC-2 week 52 (8.2 and 6.2 points), with improvements also observed across RSBQ domains and CGI-I. AEs were predominantly mild to moderate, especially among continuers. TRO continuers showed gradual dose reduction during trials with stabilization post-launch (~ 40 ml), while TRO non-continuers showed fluctuations throughout; post-launch %TDD showed minimal change of ~ 92.7% (month 1) and ~ 91.0% (month 12) among TRO continuers. Average time on TRO among continuers was 4.3 years from baseline through available real-world follow-up.</p><p><strong>Conclusion: </strong>Approximately 75% of LILAC-2 participants continued TRO post-approval; all persisted for ≥ 12 months post-launch and exhibited stable dosing patterns. Both groups demonstrated clinically meaningful RSBQ improvements through week 52 of LILAC-2 and predominantly mild-to-moderate AEs during LILAC-2.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149408826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Total Economic Impact of Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder. 抗水通道蛋白-4抗体阳性神经脊髓炎视谱障碍的总体经济影响。
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-11-12 DOI: 10.1007/s40120-026-01053-4
Benjamin J Osborne, Evanthia Bernitsas, Mayvis Rebeira, Nicole Betor, Caitlin Dodd, Jesus Loreto, Ashlee Olsen, Alexis C Garduno, Justin Lee, Lindsey M Przybyl, Jamie Sullivan, Jeffrey C Yu
{"title":"Total Economic Impact of Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.","authors":"Benjamin J Osborne, Evanthia Bernitsas, Mayvis Rebeira, Nicole Betor, Caitlin Dodd, Jesus Loreto, Ashlee Olsen, Alexis C Garduno, Justin Lee, Lindsey M Przybyl, Jamie Sullivan, Jeffrey C Yu","doi":"10.1007/s40120-026-01053-4","DOIUrl":"https://doi.org/10.1007/s40120-026-01053-4","url":null,"abstract":"<p><strong>Introduction: </strong>Economic impact data for anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) are generally limited to direct medical patient costs and exclude indirect, nonmedical, and uncovered healthcare patient and caregiver costs. Here, we estimated the total economic impact of AQP4-Ab+ NMOSD in 2024 on US patients and caregivers.</p><p><strong>Methods: </strong>This study consisted of two portions: an independent, electronically administered survey to capture indirect, nonmedical, and uncovered healthcare costs of AQP4-Ab+ NMOSD from 2023 to patients and caregivers (adjusted for inflation to 2024 dollars); and a retrospective, matched cohort claims analysis to estimate excess direct medical costs of AQP4-Ab+ NMOSD in 2024 to patients. Adults living in the USA or its territories were eligible. Annual costs for patients were calculated as the sum of weighted average indirect, nonmedical, uncovered healthcare, and excess direct costs, multiplied by the US prevalence of AQP4-Ab+ NMOSD. Annual cost for caregivers was calculated as the sum of unweighted average indirect, nonmedical, and uncovered healthcare costs, multiplied by the estimated prevalence of patients with AQP4-Ab+ NMOSD with a caregiver.</p><p><strong>Results: </strong>Of 258 respondents, 209 were patients (female, 76%; mean ± SD age, 45.1 ± 12.6 years; 44% reported a relapse in 2023; 53% had an informal caregiver) and 49 were caregivers (female, 57%; mean ± SD age, 42.1 ± 13.6 years). Estimated total economic impact of AQP4-Ab+ NMOSD in 2024 dollars was $1.06 billion (excess direct medical costs, $574.2 million [54%]; patient indirect, nonmedical, and uncovered healthcare costs, $315.3 million [30%]; caregiver indirect, nonmedical, and uncovered healthcare costs, $171.5 million [16%]). Average annual indirect, nonmedical, and uncovered healthcare costs were $51,513/patient and $54,036/caregiver.</p><p><strong>Conclusion: </strong>Indirect, nonmedical, and uncovered healthcare costs comprise approximately half the total economic impact of AQP4-Ab+ NMOSD. These results show the importance of treating patients with optimal therapies to reduce the burden on patients and caregivers. Graphical Abstract is available with this article.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149408903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perceived Quality of Treatment Decisions and Determinants of Decisional Conflict in Early-Stage Relapsing-Remitting Multiple Sclerosis. 早期复发-缓解型多发性硬化症治疗决策的感知质量和决策冲突的决定因素。
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-11-12 DOI: 10.1007/s40120-026-01078-9
Inés González-Suárez, Elena García-Arcelay, Jacobo Caruncho, Antonio Candeliere-Merlicco, Aida Orviz, Jesús Martín-Martínez, Raquel Piñar, Elena Álvarez-Rodríguez, Eva M Pacheco, Laura Borrega, Ignacio Casanova, Ana B Caminero, José L Sánchez-Menoyo, Montserrat Gómez-Gutiérrez, Olga Carmona, Carmen Calles, Miguel A Hernández, Pablo López-Muñoz, Ángel Pérez-Sempere, Jorge Maurino
{"title":"Perceived Quality of Treatment Decisions and Determinants of Decisional Conflict in Early-Stage Relapsing-Remitting Multiple Sclerosis.","authors":"Inés González-Suárez, Elena García-Arcelay, Jacobo Caruncho, Antonio Candeliere-Merlicco, Aida Orviz, Jesús Martín-Martínez, Raquel Piñar, Elena Álvarez-Rodríguez, Eva M Pacheco, Laura Borrega, Ignacio Casanova, Ana B Caminero, José L Sánchez-Menoyo, Montserrat Gómez-Gutiérrez, Olga Carmona, Carmen Calles, Miguel A Hernández, Pablo López-Muñoz, Ángel Pérez-Sempere, Jorge Maurino","doi":"10.1007/s40120-026-01078-9","DOIUrl":"https://doi.org/10.1007/s40120-026-01078-9","url":null,"abstract":"<p><strong>Introduction: </strong>Selecting a disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) is a preference-sensitive decision where shared decision-making (SDM) is essential. This study aimed to evaluate the perceived quality of the SDM process and identify independent determinants of decisional conflict among patients with early-stage RRMS.</p><p><strong>Methods: </strong>This non-interventional, cross-sectional, multicenter study across 16 Spanish neuroimmunology clinics evaluated adults with early RRMS (≤ 3 years disease duration from diagnosis) receiving DMTs. SDM process quality and decisional conflict were assessed using the AGA-25 questionnaire and the SURE tests, respectively. Multivariable logistic regression models were constructed to identify independent determinants of high process satisfaction and decisional conflict.</p><p><strong>Results: </strong>The evaluable population comprised 145 patients (mean age 37.6 years, 69.0% female). Participants evaluated the SDM process favorably (mean total AGA-25 score 67.1 [SD 9.1]). High process satisfaction was reported by 26.2% of patients (n = 38). In multivariable analysis, male sex and a higher total number of relapses since disease onset were associated with significantly lower odds of high process satisfaction, whereas higher decisional certainty was an independent positive determinant. Clinically significant decisional conflict was present in 27.1% of participants (n = 36). In the multivariable model, greater illness-related uncertainty, a more threatening illness perception, and higher fatigue impact independently increased the likelihood of decisional conflict.</p><p><strong>Conclusion: </strong>Although patients with early-stage RRMS generally report a favorable overall perception of collaborative treatment selection, high process satisfaction is attained by only approximately one-quarter of patients. Furthermore, clinically significant decisional conflict affects over 27% of individuals early in their disease course. This decisional distress is driven predominantly by the subjective emotional and perceptual burden of living with MS, rather than objective physical disability.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149408827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anxiety and Depression Symptoms During CGRP-Targeted Therapy in Patients with Migraine: A Retrospective Cohort Study from the United Arab Emirates. 偏头痛患者在cgrp靶向治疗期间的焦虑和抑郁症状:一项来自阿拉伯联合酋长国的回顾性队列研究
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-11-11 DOI: 10.1007/s40120-026-01082-z
Taoufik Alsaadi, Ahsan H Khandoker, Athra Alkhateri, Mohammad Saidam, Khaled Hamoulila, Reem Suliman
{"title":"Anxiety and Depression Symptoms During CGRP-Targeted Therapy in Patients with Migraine: A Retrospective Cohort Study from the United Arab Emirates.","authors":"Taoufik Alsaadi, Ahsan H Khandoker, Athra Alkhateri, Mohammad Saidam, Khaled Hamoulila, Reem Suliman","doi":"10.1007/s40120-026-01082-z","DOIUrl":"https://doi.org/10.1007/s40120-026-01082-z","url":null,"abstract":"<p><strong>Introduction: </strong>Anxiety and depressive symptoms are common in migraine. Whether calcitonin gene-related peptide (CGRP)-targeted therapies improve these symptoms, and whether improvement is coupled to headache reduction, remains unclear.</p><p><strong>Methods: </strong>This was a single-center, retrospective, descriptive pre-post cohort study of adults with migraine and documented anxiety and/or depression initiating a CGRP monoclonal antibody or gepant in the United Arab Emirates (UAE). Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) scores at baseline and 6 months post treatment initiation were compared using the Wilcoxon signed-rank test. Responder rates (≥ 4-point drop in GAD-7 score, ≥ 5-point drop in PHQ-9 score) were computed among patients able to reach each threshold. Between-molecule differences were tested using the Kruskal-Wallis test. Spearman correlation was used to explore the association between change in monthly migraine days (ΔMMD) and mood change.</p><p><strong>Results: </strong>Of the 121 adults who initiated treatment, 113 had paired baseline and 6-month score data (mean [± standard deviation] age 38.9 ± 9.5 years; 83.2% female; 55.8% chronic migraine). At 6 months, the GAD-7 score had fallen from 6.0 ± 4.0 to 2.7 ± 2.9 and the PHQ-9 score had dropped from 9.3 ± 4.9 to 4.3 ± 3.7 (both p < 0.001). MMD fell from 9.1 ± 5.1 to 3.0 ± 2.6 (p < 0.001). Responder rates were 59.8% (49/82) for adults according to GAD-7 scores and 54.8% (51/93) according to PHQ-9 scores. Scores decreased within every CGRP-targeted molecule subgroup, with no detectable between-molecule differences (Kruskal-Wallis p = 0.34 for ΔGAD-7; p = 0.68 for ΔPHQ-9). ΔMMD correlated only weakly with mood change (ρ = 0.04 for ΔGAD-7; ρ = 0.15 for ΔPHQ-9; both non-significant). A worsening PHQ-9 item 9 response (thoughts of death or self-harm) was recorded in one of 113 patients.</p><p><strong>Conclusion: </strong>CGRP-targeted therapies were associated with significant reductions in anxiety and depressive symptoms in this UAE cohort, although the eptinezumab and atogepant subgroups were small. No detectable association was found between changes in migraine days and mood scores. These hypothesis-generating findings warrant confirmation in controlled, prospective studies.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Efficacy of Adjunctive Cenobamate by Focal Seizure Subtypes: Open-Label Extension of a Randomized Clinical Study in a Multinational Asian Population. 局灶性癫痫亚型的长期疗效:一项亚洲多国人群随机临床研究的开放标签扩展。
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-11-03 DOI: 10.1007/s40120-026-01074-z
Peimin Yu, Xintong Wu, Ling Chen, Eunyeong Choe, Louis Ferrari, Kyoung Heo, Seung Bong Hong, Koji Iida, Yong Heui Jeon, Jiwon Jung, Marc Kamin, Kensuke Kawai, Ji Hyun Kim, Myung Won Kim, Sang Kun Lee, Jungshin Park, William E Rosenfeld, Tiancheng Wang, Takamichi Yamamoto, Sunita N Misra
{"title":"Long-Term Efficacy of Adjunctive Cenobamate by Focal Seizure Subtypes: Open-Label Extension of a Randomized Clinical Study in a Multinational Asian Population.","authors":"Peimin Yu, Xintong Wu, Ling Chen, Eunyeong Choe, Louis Ferrari, Kyoung Heo, Seung Bong Hong, Koji Iida, Yong Heui Jeon, Jiwon Jung, Marc Kamin, Kensuke Kawai, Ji Hyun Kim, Myung Won Kim, Sang Kun Lee, Jungshin Park, William E Rosenfeld, Tiancheng Wang, Takamichi Yamamoto, Sunita N Misra","doi":"10.1007/s40120-026-01074-z","DOIUrl":"https://doi.org/10.1007/s40120-026-01074-z","url":null,"abstract":"<p><strong>Introduction: </strong>To evaluate adjunctive cenobamate efficacy by focal seizure subtype during the open-label extension (OLE) of a phase 3 randomized, double-blind, placebo-controlled study (C035) in Asian patients with focal seizures.</p><p><strong>Methods: </strong>Patients aged 18-70 years old with uncontrolled focal seizures despite treatment with 1-3 antiseizure medications who completed the double-blind study (n = 425) could enter the 52-week OLE, comprising a 20-week blinded conversion from placebo or 100, 200, or 400 mg/day cenobamate to a target cenobamate dose of 400 mg/day before entering a 32-week open-label maintenance phase at 300 mg/day. Percent change from double-blind baseline in 28-day seizure frequency and responder rates (e.g., ≥ 50% reduction from baseline) for focal preserved consciousness with observable manifestations (FPC), focal impaired consciousness (FIC), or focal to bilateral tonic-clonic (FBTC) seizure subtypes were assessed in the open-label maintenance phase efficacy population (OLE-EM, ≥ 1 dose of study drug and any seizure data during the open-label maintenance phase). Safety and tolerability were assessed.</p><p><strong>Results: </strong>Among patients who entered the OLE, 357/410 (263 originally randomized to cenobamate; 94 who converted from placebo to cenobamate) were included in the OLE-EM population. Median percent seizure frequency reductions were 84.5% for FPC (n = 65), 83.0% for FIC (n = 301), and 100% for FBTC (n = 94) in the OLE-EM population. For FPC, FIC, and FBTC subtypes, ≥ 50% responder rates were 75.4%, 73.8%, and 84.0%, respectively, and 100% responder rates were 23.1%, 28.2%, and 58.5%. Among patients entering the OLE, 84.6% (347/410) completed the 52 weeks of treatment with cenobamate. The most common treatment-emergent adverse events were dizziness, somnolence, gamma-glutamyl transferase increased, and COVID-19 infection.</p><p><strong>Conclusions: </strong>During the C035 OLE maintenance phase, high seizure frequency reductions were seen for FPC, FIC, and FBTC focal seizure subtypes. Cenobamate was generally well tolerated, and the results were consistent with the double-blind treatment study. Graphical abstract available for this article.</p><p><strong>Trial registration: </strong>NCT04557085 (registered September 14, 2020).</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient Preferences for Self-Administered Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. 慢性炎症性脱髓鞘性多神经病变患者对自体皮下免疫球蛋白治疗的偏好。
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-10-30 DOI: 10.1007/s40120-026-01062-3
Batyrkhan Kuatov, Sarah-Jane Cashmore, Noemi Hahn, Julia Braverman, Laurence Undreiner, Shicheng Weng, Ben Gibbons
{"title":"Patient Preferences for Self-Administered Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy.","authors":"Batyrkhan Kuatov, Sarah-Jane Cashmore, Noemi Hahn, Julia Braverman, Laurence Undreiner, Shicheng Weng, Ben Gibbons","doi":"10.1007/s40120-026-01062-3","DOIUrl":"https://doi.org/10.1007/s40120-026-01062-3","url":null,"abstract":"<p><strong>Introduction: </strong>Subcutaneous immunoglobulin (SCIG) therapy is increasingly used to treat chronic inflammatory demyelinating polyneuropathy (CIDP). To support patient-centered care and improve adherence, we evaluated which SCIG treatment attributes matter most to patients and compared experiences using pre-filled syringes (PFS) versus vials.</p><p><strong>Methods: </strong>A conjoint analysis was conducted with n = 187 Ig-using patients with CIDP from the USA and Canada to quantify the relative importance of attributes related to self-administered subcutaneous therapy. Following this, a survey of n = 68 SCIG users assessed real-world experiences and preferences with PFS and vial-based administration, including outcomes among patients with CIDP who switched to PFS.</p><p><strong>Results: </strong>The main drivers of preference in subcutaneous therapies were ease of preparation (31% of relative importance) and likelihood of getting sick after infusion (27% of relative importance). Injection volume and skin reaction ranked third (23% of relative importance). In the survey, PFS users reported that administering their infusions was more convenient (7-point scale, median 6 vs median 5, respectively) and they were more confident administering their infusions than vial users (completely or very confident, 98% vs 84%, respectively). More PFS users reported feeling \"better than usual\" within the first day post-infusion compared with vial users (51% vs 20%, respectively). Among patients who switched from vials to PFS (n = 17), 71% reported higher treatment satisfaction, 82% found PFS more convenient, and 65% reported faster administration with PFS.</p><p><strong>Conclusions: </strong>PFS aligns with key preference drivers for self-administered SCIG therapy in CIDP compared to vials. These findings highlight the value of integrating patient-prioritized treatment attributes and preferences into clinical decision-making.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Global Burden of Migraine: A Narrative Review and Expert Perspective on Disease Burden, Unmet Needs, and Policy Priorities. 偏头痛的全球负担:疾病负担、未满足的需求和政策优先事项的叙述回顾和专家观点。
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-10-30 DOI: 10.1007/s40120-026-01076-x
João Victor Rocha, Cristina Tassorelli, Debashish Chowdhury, Elena Ruiz de la Torre, Elizabeth Leroux, Mauro Eduardo Jurno, Rob Music, Taoufik Alsaadi, Teresa Marinetti
{"title":"The Global Burden of Migraine: A Narrative Review and Expert Perspective on Disease Burden, Unmet Needs, and Policy Priorities.","authors":"João Victor Rocha, Cristina Tassorelli, Debashish Chowdhury, Elena Ruiz de la Torre, Elizabeth Leroux, Mauro Eduardo Jurno, Rob Music, Taoufik Alsaadi, Teresa Marinetti","doi":"10.1007/s40120-026-01076-x","DOIUrl":"https://doi.org/10.1007/s40120-026-01076-x","url":null,"abstract":"<p><strong>Background: </strong>Migraine is a highly prevalent and disabling neurological disorder that imposes a substantial health, social, and economic burden, including significant impacts on workforce participation and productivity. Despite advances in treatment and increased recognition of its burden, migraine remains underdiagnosed, undertreated, and insufficiently prioritized in many health systems. Barriers across the patient journey continue to limit timely diagnosis, effective management, and equitable access to care.</p><p><strong>Aims: </strong>This Global Migraine narrative review and expert perspective seek to promote international alignment on the burden of migraine and provide evidence-informed guidance to improve care, workplace support, and policy development worldwide.</p><p><strong>Methods: </strong>A two-stage methodology was applied. First, a structured non-systematic literature review synthesized evidence on migraine epidemiology, socioeconomic burden, quality of life, workplace productivity, policies, access to care, and the patient journey. Second, findings were validated and refined through consultations with international experts representing diverse geographies, healthcare systems, and levels of migraine policy development. Two virtual expert panel meetings were held in December 2025 and March 2026, respectively, supported by offline reviews and follow-up consultations.</p><p><strong>Results: </strong>Six key areas of unmet need were identified: diagnosis and disease recognition; knowledge and education; social and psychological impact; access to care; availability and affordability; and treatment quality. Migraine remains largely absent from national health strategies, contributing to fragmented care and inadequate resource allocation. The call-to-action outlines priority recommendations, key stakeholders, and implementation considerations to address these gaps across different health system contexts.</p><p><strong>Conclusion: </strong>Migraine should be recognized as a public health and economic priority. Coordinated strategies are needed to improve diagnosis, care pathways, treatment access, and productivity outcomes, while strengthening global collaboration and policy alignment.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness Analysis of Disease-Modifying Therapies for Early Alzheimer's Disease in China. 中国早期阿尔茨海默病疾病修饰疗法的成本-效果分析
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-10-30 DOI: 10.1007/s40120-026-01073-0
Siyao Dong, Kaihua Gao, Wei Lin, Wen Chen, Hailian Liu, Qingchen Wang, Zhanmiao Yi
{"title":"Cost-Effectiveness Analysis of Disease-Modifying Therapies for Early Alzheimer's Disease in China.","authors":"Siyao Dong, Kaihua Gao, Wei Lin, Wen Chen, Hailian Liu, Qingchen Wang, Zhanmiao Yi","doi":"10.1007/s40120-026-01073-0","DOIUrl":"https://doi.org/10.1007/s40120-026-01073-0","url":null,"abstract":"<p><strong>Introduction: </strong>Lecanemab and donanemab are disease-modifying therapies for early Alzheimer's disease, but their long-term economic value in China remains uncertain. This study evaluated their long-term cost-effectiveness in China.</p><p><strong>Methods: </strong>A lifetime Markov model compared lecanemab plus standard of care (SoC), donanemab plus SoC, and SoC alone from the Chinese healthcare system and societal perspectives. Treatment cohorts were stratified by apolipoprotein E ε4 genotype. The model incorporated Chinese real-world costs, treatment-related adverse events, discontinuation, and post-discontinuation benefits. Outcomes included costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way and probabilistic sensitivity analyses assessed parameter uncertainty, while scenario analyses examined drug prices, treatment populations, administration routes, and efficacy assumptions.</p><p><strong>Results: </strong>From the healthcare system perspective, ICERs (in United States dollars [USD]) for lecanemab plus SoC and donanemab plus SoC were USD 309,841.194/QALY and USD 232,793.705/QALY, respectively. Corresponding societal ICERs were USD 300,434.358/QALY and USD 212,256.111/QALY. All estimates exceeded the prespecified willingness-to-pay threshold. The ICER for lecanemab was driven mainly by treatment efficacy and drug price, whereas donanemab was most sensitive to the duration of residual treatment effect. Varying the treatment-eligible population had limited impact on the ICERs. From the healthcare system perspective, ICERs ranged from USD 304,889.902 to USD 310,071.658/QALY for lecanemab and USD 211,226.601 to USD 240,400.661/QALY for donanemab; the corresponding societal ranges were USD 293,467.938-312,810.263/QALY and USD 204,513.613-214,437.087/QALY. At assumed United States prices for subcutaneous lecanemab, intravenous administration had a slightly lower ICER from the healthcare system perspective (USD 309,841.194/QALY versus USD 317,811.454/QALY), whereas all-subcutaneous administration had a slightly lower societal ICER (USD 298,027.332/QALY versus USD 300,434.358/QALY).</p><p><strong>Conclusion: </strong>Neither lecanemab nor donanemab was cost-effective at current Chinese prices. Patient selection had limited impact. The lower ICER for donanemab depended on the assumed residual treatment effect after discontinuation.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concepts and Assessment of Fatigue in Myasthenia Gravis: A Scoping Review. 重症肌无力疲劳的概念和评估:范围综述。
IF 4.7 3区 医学
Neurology and Therapy Pub Date : 2026-10-28 DOI: 10.1007/s40120-026-01069-w
Sarah Hoffmann, Nishtha Chandra, Channa Hewamadduma, Lorenzo Maggi, Michael D Weiss, Jos Bloemers, Veronica Porkess, Thaïs Tarancón, Henry J Kaminski, John Vissing
{"title":"Concepts and Assessment of Fatigue in Myasthenia Gravis: A Scoping Review.","authors":"Sarah Hoffmann, Nishtha Chandra, Channa Hewamadduma, Lorenzo Maggi, Michael D Weiss, Jos Bloemers, Veronica Porkess, Thaïs Tarancón, Henry J Kaminski, John Vissing","doi":"10.1007/s40120-026-01069-w","DOIUrl":"https://doi.org/10.1007/s40120-026-01069-w","url":null,"abstract":"<p><strong>Introduction: </strong>Fatigue is a burdensome symptom for many patients with myasthenia gravis (MG) and severely reduces quality of life. Fatigue in MG is described using multiple, partially overlapping concepts, or domains, that are not uniformly defined. The aims of this scoping review were to identify and summarise fatigue concepts related to MG, to review fatigue assessment scales and to evaluate their clinical interpretability, including fatigue caseness, fatigue severity, and clinically meaningful change thresholds.</p><p><strong>Methods: </strong>Searches were conducted to identify clinical and observational studies published between 1 January 1990 and 28 February 2025, on PubMed, Embase, ClinicalTrials.gov, EudraCT and Cochrane Library, which presented original research in MG and used a quantitative measurement to assess fatigue. Following identification of fatigue concepts and assessment scales, a targeted secondary search was performed to ascertain clinically meaningful change thresholds for each scale.</p><p><strong>Results: </strong>Seventy-six studies were included. Thirteen fatigue concepts including mental, physical and general fatigue were identified and summarised, with several concepts overlapping. Eighteen fatigue scales used in MG research were identified. Only two scales, Quality of Life in Neurological Disorders Short Form Fatigue and MG Symptoms Patient-Reported Outcome Physical Fatigue, had change thresholds validated in MG.</p><p><strong>Conclusion: </strong>This review highlights heterogeneity in fatigue concepts and assessment approaches used in MG. No single fatigue scale fulfils the key clinical requirements (assessment of caseness, fatigue severity, and presence of a validated clinically meaningful change threshold). Clearer conceptual definitions and further validation of fatigue scales in MG may improve clinical interpretability.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书